Market Overview:
The global alveolar rhabdomyosarcoma treatment market is expected to grow at a CAGR of 6.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of alveolar rhabdomyosarcoma, rising awareness about the disease, and technological advancements in cancer treatments. Based on type, the global alveolar rhabdomyosarcoma treatment market is segmented into surgical operation, chemotherapy, and radiotherapy. The surgical operation segment is expected to account for the largest share of the global market in 2018. This segment is further divided into traditional surgery and minimally invasive surgery. The traditional surgery segment accounted for the majority share of this sub-segment in 2017 and is projected to maintain its dominance during the forecast period owing to its low cost and high efficacy as compared with minimally invasive surgery procedures.
Product Definition:
Alveolar rhabdomyosarcoma is a rare cancerous tumor that arises from muscle cells in the lungs. Treatment typically includes surgery, radiation therapy, and chemotherapy.
Surgical Operation:
Surgical operation, also called as rhabdomyosarcoma surgery or rhizotomy is a method used to treat patients with muscle spasms and rigid muscles. The surgical procedure involves the removal of part of the nerve that supplies the muscle with too much information (nerve sectioning). This procedure is most effective for children under five years of age.
Chemotherapy:
Chemotherapy is the use of drugs or chemical substances to treat cancer. Chemotherapy includes a group of medical treatments used to inhibit or kill the cancerous cells. The most common types of chemotherapies used are alkylating agents, antimetabolites, plant derivatives, and cytotoxic agents. Alkylating agents block the synthesis of RNA and DNA in cells; this leads to cell death by dissociation of nucleic acids from the proteins they bind to.
Application Insights:
The others segment held the largest share of the global alveolar rhabdomyosarcoma treatment market in 2017. This segment includes patients referred from other hospitals or clinics, and those who are treated at home by their family doctors. The others segment is expected to witness significant growth over the forecast period owing to increasing awareness about various treatments for children with cancer, especially in developing countries such as India and China. In addition, a rise in availability of advanced healthcare facilities is also anticipated to boost alveolar rhabdomyosarcoma treatment demand globally during the study period.
Hospitals are estimated to be one of the fastest-growing application segments due to rising awareness about early diagnosis and effective treatments for pediatric cancers coupled with an increase in funding support for hospitalization costs associated with these diseases.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption of advanced technologies and favorable reimbursement policies. The U.S.-based company Pfizer Inc., has provided funds for research activities conducted by sarcoma patients association in collaboration with Columbia University Medical Center (CUMC). In addition, approval and launch of new products is also expected to boost regional growth over the forecast period. For instance, in February 2018, Eisai Co., Ltd., a subsidiary of Japan’s Ministry of Health, Labor & Welfare (MHLW), received FDA approval for Xofigo treatment regimen comprising two courses: chemotherapy followed by immunotherapy drug elaprase infusion at home (UH).
Growth Factors:
- Increasing incidence of Alveolar Rhabdomyosarcoma
- Growing awareness about Alveolar Rhabdomyosarcoma Treatment
- Rising demand for better and advanced Alveolar Rhabdomyosarcoma Treatment options
- Technological advancements in the field of Alveolar Rhabdomyosarcoma Treatment
- Availability of government funding for research and development in the field of Alveolar Rhabdomyosarcoma Treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Alveolar Rhabdomyosarcoma Treatment Market Research Report
By Type
Surgical Operation, Chemotherapy, Radiotherapy
By Application
Hospitals, Clinics, Others
By Companies
Eli Lilly, GlaxoSmithKline, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, Oasmia, Celgene, Pfizer, Johnson & Johnson
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
198
Number of Tables & Figures
139
Customization Available
Yes, the report can be customized as per your need.
Global Alveolar Rhabdomyosarcoma Treatment Market Report Segments:
The global Alveolar Rhabdomyosarcoma Treatment market is segmented on the basis of:
Types
Surgical Operation, Chemotherapy, Radiotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- GlaxoSmithKline
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Roche
- Oasmia
- Celgene
- Pfizer
- Johnson & Johnson
Highlights of The Alveolar Rhabdomyosarcoma Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Surgical Operation
- Chemotherapy
- Radiotherapy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Alveolar Rhabdomyosarcoma Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best treatment for alveolar rhabdomyosarcoma will vary depending on the specific characteristics of the tumor and individual patient. However, some common treatments for alveolar rhabdomyosarcoma include surgery to remove the tumor, chemotherapy or radiation therapy to destroy cancer cells in the tumor, and a combination of these two therapies.
Some of the key players operating in the alveolar rhabdomyosarcoma treatment market are Eli Lilly, GlaxoSmithKline, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, Oasmia, Celgene, Pfizer, Johnson & Johnson.
The alveolar rhabdomyosarcoma treatment market is expected to grow at a compound annual growth rate of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Alveolar Rhabdomyosarcoma Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Alveolar Rhabdomyosarcoma Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Alveolar Rhabdomyosarcoma Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Alveolar Rhabdomyosarcoma Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Alveolar Rhabdomyosarcoma Treatment Market Size & Forecast, 2018-2028
4.5.1 Alveolar Rhabdomyosarcoma Treatment Market Size and Y-o-Y Growth
4.5.2 Alveolar Rhabdomyosarcoma Treatment Market Absolute $ Opportunity
Chapter 5 Global Alveolar Rhabdomyosarcoma Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Type
5.2.1 Surgical Operation
5.2.2 Chemotherapy
5.2.3 Radiotherapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Alveolar Rhabdomyosarcoma Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Alveolar Rhabdomyosarcoma Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Alveolar Rhabdomyosarcoma Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Type
9.6.1 Surgical Operation
9.6.2 Chemotherapy
9.6.3 Radiotherapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Alveolar Rhabdomyosarcoma Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Type
10.6.1 Surgical Operation
10.6.2 Chemotherapy
10.6.3 Radiotherapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Alveolar Rhabdomyosarcoma Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Type
11.6.1 Surgical Operation
11.6.2 Chemotherapy
11.6.3 Radiotherapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Alveolar Rhabdomyosarcoma Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Type
12.6.1 Surgical Operation
12.6.2 Chemotherapy
12.6.3 Radiotherapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Alveolar Rhabdomyosarcoma Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Type
13.6.1 Surgical Operation
13.6.2 Chemotherapy
13.6.3 Radiotherapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Alveolar Rhabdomyosarcoma Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Alveolar Rhabdomyosarcoma Treatment Market: Competitive Dashboard
14.2 Global Alveolar Rhabdomyosarcoma Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly
14.3.2 GlaxoSmithKline
14.3.3 Boehringer Ingelheim
14.3.4 Bristol-Myers Squibb
14.3.5 Roche
14.3.6 Oasmia
14.3.7 Celgene
14.3.8 Pfizer
14.3.9 Johnson & Johnson
